<DOC>
	<DOC>NCT00563316</DOC>
	<brief_summary>The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.</brief_summary>
	<brief_title>Effect of Panitumumab on the Pharmacokinetics of Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Pathologically confirmed unresectable metastatic colorectal cancer (mCRC) which has progressed on at least one prior 5fluorouracil (5FU)containing chemotherapy regimen Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Life expectancy of ≥ 3 months as documented by the investigator Baseline actual body weight ≤ 160 kg Competent to comprehend, sign, and date a written Institutional Review Board (IRB) approved informed consent form before any studyspecific procedures are performed Treatment with radiotherapy ≤ 14 days before enrollment. Patients must have recovered from all radiotherapyrelated toxicities Known presence of central nervous systems (CNS) metastases Any prior malignancy (except for nonmelanomatous skin cancer or in situ cervical cancer) other than the study disease, unless treated with curative intent with no evidence of disease ≤ 2 years before enrollment History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as &gt; Common Terminology Criteria for Adverse Events (CTCAE version 3) grade 2 Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment UGT1A1*28 TA7/7, TA7/8, TA8/8 genetic polymorphisms; Gilbert's Disease Treatment with CYP3A4 enzyme inhibiting or inducing medications ≤ 2 weeks before enrollment Prior antiepidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib) Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before enrollment Subjects requiring immunosuppressive agents (eg, methotrexate and cyclosporine), however corticosteroids are allowed Major surgery &lt; 28 days prior to enrollment or minor surgery (excluding catheter placement) &lt; 14 days before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>irinotecan</keyword>
	<keyword>EGFr</keyword>
	<keyword>epidermal growth factor</keyword>
</DOC>